TN
Tenaya Therapeutics, Inc.
TNYA · NASDAQ
$0.64 -3.03% (-$0.02)
1M -8.58%
Market Cap $138.9M
P/E Ratio -
Div. Yield -
ROE 108.05%
Bulios Fair Price
$0.49
23.4% downside
Current Price
$0.64
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TNYA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/B 2.00x
P/S 104.03x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 20.29%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 7,929.89%
Gross margin 263.67%
FCF margin 5,380.75%
Quality
0 /100
Poor ROA 110.24%
ROIC 136.78%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 4.52x
Debt/Equity 0.06x
Debt/Assets N/A
Stability
42 /100
Moderate Profitable years 0
Beta 2.78x
EPS volatility 16.47%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TNYA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Faraz Ali
Employees
70
Headquarters
South San Francisco
Upcoming events
11 NOV
Earnings
Upcoming earnings report